Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c16d2144a81bfa32a665dca1e93c3d37 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2014-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7326e696782e3e7bd67dc86981519f51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af62f2c9ef5243e1f3b4e295ce85bc51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_038757db8ddeef4c6fbb6b46fe7a7df7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_993f16dab7959784c2d44676a1f4cd70 |
publicationDate |
2014-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2786765-A2 |
titleOfInvention |
Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor |
abstract |
Provided is a composition for use in combination therapy for prevention or treatment of a cancer including a FGFR inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof as active ingredients. The composition for use in combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment. |
priorityDate |
2013-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |